Podcast: Novartis, ML&P and ex-GSK counsel on COVID pools

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Podcast: Novartis, ML&P and ex-GSK counsel on COVID pools

re-podcast-logo.png

Guests debate how patent pools could be used to ensure global access to COVID treatments and vaccines, as well as how the pandemic has changed the IP system


To listen to the podcast, which is nearly 50 minutes, click the link below.

For the first Managing IP podcast, Charlotte Kilpatrick and IP experts discussed the ramifications of the COVID-19 crisis on the patent system and how the virus could change how pharma innovators conduct research and collaborate.

A highlight was a debate on the role patent pools could play to accelerate research for COVID treatments and vaccines. Ellen 't Hoen, director of the Medicines Law and Policy research institute in the Netherlands, stressed the importance for pharma innovators to use patent pools as a way to ensure global access to the vaccines once they become available. She pointed to the example of the Medicines Patent Pool, which negotiates licences for HIV and tuberculosis medications with generics companies, which can produce treatments at an affordable cost for developing countries.

David Rosenberg, former vice president of IP policy at GSK, agreed that a patent pool could be one solution among many to ensure access, but added he doesn’t believe a pool will be the ideal way for companies to conduct business and that innovators are more confident to negotiate with generics companies they already know. 

Corey Salsberg, vice president and global head of IP affairs at Novartis in Washington DC, noted that because tackling COVID-19 could involve multiple vaccines as well as treatments for those with advanced symptoms, a single patent pool might not be the best solution to ensure access.

Enjoy the podcast. 








more from across site and SHARED ros bottom lb

More from across our site

A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
Gift this article